Applied Therapeutics (NASDAQ:APLT) Issues Earnings Results

Applied Therapeutics (NASDAQ:APLT) issued its quarterly earnings results on Monday. The company reported ($0.24) EPS for the quarter, Zacks reports.

Applied Therapeutics Stock Down 0.7 %

APLT traded down $0.00 on Monday, reaching $0.37. The company’s stock had a trading volume of 1,397,626 shares, compared to its average volume of 3,120,046. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The stock has a 50 day moving average of $0.51 and a two-hundred day moving average of $3.29. The company has a market capitalization of $42.94 million, a price-to-earnings ratio of -0.23 and a beta of 1.88.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on APLT. Royal Bank of Canada decreased their target price on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. William Blair downgraded Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 23rd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.